expect posit still
wood chop
initi coverag apelli neutral rate target price aplss lead product
target central converg point complement cascad target
may address broad rang indic carri substanti option see
potenti nich role pnh though think share current fairli valu
given unknown actual commerci opportun indic
pnh high probabl indic commerci opportun alreadi
appear reflect stock see pnh rel de-risk indic base
diseas biolog data gener date think opportun
inhibit captur share roughli patient believ well-establish
standard care evolv treatment landscap may cap substanti upsid
expect read late dec expect debat clinic
meaning result might expect investor focu rel hb increas
achiev potenti reduct transfus burden believ
increment clinic updat beyond pegasu compani expect start
studi cad earli see potenti valu cad though unlik pnh
less-establish market expect sanofi readout sutimlimab
cad read-through option indic final
ga readout could meaning valu inflect point stock
program contenti investor physician express
skeptic believ investor see ga specul call option point
unless pnh commerci opportun expand beyond initi estim
upsid stock might limit next month
valuation/risk target price base dcf project use
discount rate incorpor po pnh po apl-
cad po ga risk thesi clinic regulatori
commerci headwind potenti financ
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
apelli clinical-stag biopharmaceut compani focus
develop novel therapeut compound treat diseas
inhibit complement system compani lead product apl-
develop pnh ga cad
blue sky reflect probabl success po
pnh po geograph
atrophi po cold agglutinin diseas
 dcf wieght lower discount rate
grey sky reflect failur pnh studi
lead elimin pnh/cad program valuat
concern program weight
 close
tabl content
debat expect pushback
inhibit may offer differenti efficaci subset patient well-
manag inhibitor pnh
aiha offer addit sourc valu creation hematolog
system nephropathi addit sourc option
geograph atrophi could drive upsid option appear fairli price
valuat risk
initi coverag apelli neutral rate target price apelliss lead
product complement inhibitor current phase clinic trial treatment
paroxysm nocturn hemoglobinuria pnh life-threaten blood diseas
geograph atrophi ga chronic progress eye diseas addit earlier-stag
program autoimmun hemolyt anemia aiha rare blood cell disord
complement-medi nephropathi kidney diseas see potenti nich role
pnh though think share current fairli valu given risk associ
commerci opportun indic
see pnh rel de-risk indic base diseas biolog data gener
date think opportun inhibit captur share roughli
patient believ well-establish standard care alxn soliri ultomiri
evolv treatment landscap may limit substanti upsid model peak
opportun head-to-head trial versu soliri pegasu expect read
dec data disclos late earli agre
consensu view gener expect posit outcom think like
debat clinic meaning result investor focu rel
hemoglobin hb increas achiev potenti reduct transfus burden
gaug abil competit wrest share away soliris/ultomiri
within hematolog believ develop cold agglutinin diseas cad may offer anoth
sourc potenti upsid share see potenti lead clinic benefit
base data date show meaning improv hb set diseas
patholog de-risk competitor complement inhibitor believ cad could
peak revenu opportun though unlik pnh yet well-develop
establish market like go second complement inhibitor
market condit
believ ga program carri greater risk promis efficaci signal demonstr
phase studi sever unknown rel overal product profil expect
phase program help clarifi open question readout like
expect investor debat around ga program continu push/pul
substanti theoret off-set investor/physician skeptic program
final upcom updat asn kidney week could add anoth sourc
option compani alreadi commit advanc clinic develop
indic howev given rel small sampl size lack clear comp frame
earli data posit expect potenti upsid stock event may limit
arriv target price use blended-valu approach includ
product base dcf estim premium dcf use discount rate
incorpor po pnh po cad po
ga risk thesi clinic regulatori commerci headwind
potenti financ
credit suiss biotech short-term outlook investor like focus
decemb pegasu readout pnh though think posit outcom trial
reflect stock current price also expect sanofi readout
sutimlimab cad read-through option indic
credit suiss biotech long-term outlook long-term expect stock
trade mostli materi theoret option actual
launch perform drug pnh ga data could meaning valu
inflect point though think difficult high convict view overal
commerci opportun point
credit suiss biotech outlook apelli could interest target
larger biopharma compani de-risk though uncertainti around final product
profil ga evolv competit landscap pnh like limit potenti
acquir set expect current investor hold high expect follow recent
transact complement space ra pharma achillion
debat expect pushback
could threshold upcom pegasu readout drive upsid
stock
upcom pegasu readout power g/dl hb
delta versu eculizumab believ achiev hurdl base clinic data
date mechan action howev clinic meaning hb
increas highli depend baselin level simpl stat-sig win slightli
may necessarili enough translat larg commerci opportun
drive upsid physician interpret data term increment hb
final hb level person reach benefit deriv near-norm level
expect payer perspect unclear type evid requir potenti
posit competit patient expect evid reduct transfus
burden play import role
manag recent indic pegasu studi enrol subject
rel high transfus burden transfus per year believ see signal
transfus reduct possibl without risk simplifi use averag could
expect subject studi transfus four-month period
subject arm eculizumab arm benefit
transfus avoid seen lower hb level/high transfus burden popul
believ bull argument broad uptak across entir pnh popul may
weaken final would also pay attent number patient take
move twice-weekli dose regimen
work pnh wouldnt convert vast major market
believ current standard care eculizumab soliri ravulizumab ultomiri set
high bar term efficaci eas administr addit extens physician
experi safeti databas convers major patient may clear cut
inhibit carri potenti increment manag vaccin risk infect
rel inhibit demonstr amen profil date safeti
doesnt seem stick point physician
inhibit may potenti lead increment benefit pnh popul though
on-going debat exact share patient popul like benefit
inhibit base literatur review physician feedback think
reason estim nich opportun rang pnh patient
complement inhibitor develop either monotherapi combin
inhibit may help address current shortcom soliris/ultomiri could
potenti restrict opportun alexion recent announc acquisit
achillion lead asset factor inhibitor show increment efficaci
combin eculizumab tough-to-treat/incomplet respond patient
factor b/d inhibitor clinic current could develop combo
believ market share shift fairli gradual think broader uptak
front-lin therapi unlik given well-establish soliris/ultomiri sticki
natur rare diseas market dispers prescrib base us
price could import lever posit favor though uncertain
elast demand differ point think price across indic come
challeng believ price inhibitor like come next year
given pressur biosimilar novel agent think investor may current
overlook potenti price flexibl alexion may ultomiri report titl
explor strateg repric al option part complement market evolut
factor taken consider think revenu opportun
pnh like limit rang
given level unmet need size opportun could geograph atrophi
big success
beyond risk pend trial sever unknown make us cautiou
opportun physician spoke program quit skeptic
prospect diseas drug far view consensu game changer
among physician commun
unclear studi evid function benefit beyond slow diseas
believ may crucial ensur approval/reimburs ex-u market
treatment burden associ monthli intravitr inject best perform arm
fairli high especi consid advanc age patient popul
patient necessarili notic treatment benefit sinc drug may abl
slow alreadi slowli progress diseas final report new onset exud caus
concern among physician expect trial help elucid potenti
implic
 discoveri result cohortnovemb pnh top-lin result head-to-head studi late cad start trialearli ga enrol complet pnh nave enrol complet spring pnh nave datal ga top-lin result charl martineau pm univers toronto novemb
apelli develop inhibitor across multipl indic geograph
atrophi ga paroxysm nocturn hemoglobinuria pnh advanc
central converg point complement cascad regardless pathway
activ target may address broader rang indic compar
complement inhibitor current market develop though histor
difficult target
synthet cyclic peptid conjug polym bind specif
central point converg three pathway complement activ
classic lectin altern figur detail formul
intravitr inject system deliveri iv sc system dose
suppress free/intact
believ literatur support potenti safe dose inhibitor individu
lack function level suscept infect neisseria meningitid
individu lack function level streptococcu pneumonia haemophilu
influenza see risk manag vaccin
target could lead clinic benefit
broader rang indic compar
complement inhibitor offer
increment efficaci case
studi healthi volunt report seriou advers event sae treatment emerg
advers event teae lead studi drug discontinu safeti
databas continu accru expert comfort profil date
figur complement pathway converg level
lectin pathwayclass pathwayaltern reperfusionantibodiesmicroorganismsigg igmmannos sugarforeign macrophagesmembran damag cell charl martineau pm univers toronto novemb
efficaci subset patient
well-manag inhibitor pnh
see paroxysm nocturn hemoglobinuria pnh rel de-risk indic
base diseas biolog data gener date though think commerci
opportun alreadi larg bake stock current valuat
believ market share shift fairli gradual think broader uptak
front-lin therapi unlik given well-establish soliris/ultomiri
sticki natur rare diseas market dispers prescrib base us
major patient well manag mani alexion drug year
model peak pnh opportun think stock alreadi reflect
market opportun
alexion enjoy monopoli treatment paroxysm nocturn hemoglobinuria pnh
atyp hemolyt urem syndrom ahu establish soliris/ultomiri
reign standard care despit overal small target patient popul high unmet
need coupl strong efficaci premium price led soliris/ultomiri deliv
multi-billion dollar annual sale across pnh ahu franchis treat
gmg nmosd ad growth recent
alexion success complement franchis attract multipl potenti competitor
mostli pnh though second-gener product ultomiri rais bar
term efficaci administr conveni ultomiri dose iv everi eight
week vs everi two week soliri subcutan sc formul develop
howev pnh despit establish efficaci near full suppress activ subset
patient continu incomplet hematolog respons
figur despit remark efficaci patient incomplet respons soliri
case incomplet respons like driven drug plasma-concentr
breakthrough physician spoken anecdot indic patient
requir higher and/or frequent dose soliri prevent breakthrough intravascular
hemolysi red blood cell ruptur circul alexion indic
patient pnh could experi breakthrough intravascular hemolysi investor day
roughli consist report physician spoke
believ patient greater pk coverag improv dose
regimen ultomiri may success address portion case
howev evid suggest subset patient may still experi sub-optimal
hemoglobin level even optim dose inhibitor like driver
find extravascular hemolysi destruct red blood cell phagocytosi
spleen liver like driven opson upstream activ view
popul repres patient subset could deriv benefit complement
inhibitor target upstream compon
potenti caus incomplet respons solirispotenti solutionrar variantsmut soliris/ultomiri bind site render drug ineffectiveoth inhibitor target differ bind epitop target complement componentspk breakthroughlow concentr circul drugmor frequent dose and/or higher dose may address ultomirispd breakthroughincreas complement activ like owe clinic event treat underli clinic eventextravascular hemolysisremov pnh rbc liver/spleenproxim complement inhibitionbon marrow disordersbon marrow failureinadequ product rbcstreat underli aplast anemiaadapt risitano antonio et al anti-compl treatment paroxysm nocturn hemoglobinuria time proxim complement inhibit posit paper saawp ebmt frontier immunolog intravascular charl martineau pm univers toronto novemb
address popul incomplet hematolog respons
could benefit differ mechan action
studi base data collect pnh patient found patient treat
eculizumab soliri sever anem hb g/dl expert check
suggest broad major like owe extravascular hemolysi figur
detail studi also show
patient least one transfus past month
patient requir transfus past month
patient rbc degre extravascular hemolysi
present case
figur estim hemoglobin level breakdown pnh patient
compar normal individu
figur increas reticulocyt count compens
estim higher anoth studi cite alexion risitano et al blood
suggest among patient remain transfus depend
minor total patient clinic evid extravascular hemolysi howev note
small sampl size studi cite total figur detail
figur separ studi suggest extravascular hemolysi clinic evid patient
on-going debat exact patient sub-segment definit
bone marrow failur across pnh patient think reason estim
nich opportun rang could substanti increment benefit
inhibitor inhibitor though theori inhibit could util across
total pnh patient popul
posit rel agent
captur potenti share pnh market
phase data head-to-head pegasu trial expect around decemb
data disclos late apelli hope show increment benefit
hemoglobin level versu soliri pharoah studi underli
biolog anem soliri patient suggest studi like posit
much anticip competit pnh expect come multipl inhibitor
current develop novel inhibitor potenti biosimilar may
directli compet long term soliri ultomiri posit clinic differenti seem
improb difficult-to-treat patient segment on-going hemolysi like remain
unattend novel agent extravascular hemolysi like major driver
on-going symptom
potenti address unmet need captur market share
pnh either add-on monotherapi design phase program intend
highlight competit advantag prevent mediat extravascular hemolysi
establish proof-of-concept efficaci pnh
apelli conduct two phase studi pnh one treatment-nav patient
paddock add-on soliri pharoah physician spoken
believ efficaci seen date encourag potenti competit albeit
small sampl size outcom hematolog marker favor suggest
inhibitor attract hemoglobin increas
daili subcutan administr monotherapi treatment-nav
subject led normal/near-norm mean level ldh marker hemolysi efficaci
gener compar inhibitor baselin hemoglobin increas g/dl
g/dl day addit improv marker anemia reticulocyt
count bilirubin howev import highlight baselin hb level
markedli lower rel ultomiri studi g/dl nave studi g/dl
switch studi
figur led substanti ldh reduct
figur increas hb level near normal
reduct ldh rapid follow initi therapi subject achiev ldh
normal rang day
reduct ldh sustain durabl mean ldh maintain within normal rang
time point beyond day
subject respond rapidli initi therapi day mean baselin hb increas
g/dl g/dl
increas hb sustain durabl repres mean hb g/dl day
studi includ subject treat soliri least month hb g/dl
screen least one transfus month prior screen particip
enrol dose cohort major receiv higher-than-approv dose
soliri indic baselin characterist
object studi initi add-on potenti
reduct soliri label dose potenti withdraw soliri
maintain monotherapi
four subject remain studi continu receiv daili dose two
subject discontinu one owe pregnanc potenti dose
subject morbidli obes histori ms renal/urinari co-morbid
accord apelli subject physician request patient
interpret extrapol studi somewhat affect
discontinu overal consist result four subject drug along
strong biolog rational indic make us comfort result
present apelli transpar provid extens detail patient includ
individu curv show hb ldh level four subject still drug
subject saw increas hb reduct transfus requir importantli
data studi show reduct percentag pnh red blood cell
time provid addit valid support inhibit approach valuabl
therapeut altern patient
figur pharoah add-on soliri
soliri dose reduct label regimen achiev high-dos subject
 day june three four subject success discontinu soliri one
remain dose level two increas dose
remain patient two unsuccess attempt discontinu soliri approv
dose subsequ abl discontinu therapi soliri
figur patient success transit monotx
compani data interim data report sept
phase program design highlight potenti
differenti soliri
apelliss program includ registr head-to-head studi versu soliri pnh
patient hb screen refer pegasu trial primari
endpoint chang hb level week potenti venu differenti
agent
head-to-head studi versu soc design
expect highlight potenti differenti
studi incorpor run-in period subject given soliri
particip later random monotherapi soliri monotherapi arm
open-label extens period also offer opportun patient soliri arm
receiv add-on certain period time wane soliri
studi origin design sampl size subject trial actual
enrol patient power detect hb differ g/dl
vs soliri recal four subject transit soliri pharoah
increas hb versu baselin soliri monotherapi
believ trial design adequ highlight potenti advantag
inhibit also provid experi data support potenti switch patient
also note current competitor date disclos plan
conduct head-to-head studi current soc
apelli complet enrol head-to-head studi pnh june data
expect decemb recent commentari suggest data may disclos late
compani also conduct treatment-nav studi dose first patient
septemb princ studi ex-u trial patient activ arm
treat six month trial design enrol subject random
activ pbo subject placebo arm allow cross activ one
month see studi provid support data overal profil believ
placebo arm set low bar comparison
believ trial may fulli enrol spring despit potenti competit
trial enrol pegasu trial took year enrol patient
nich commerci opportun bake stock
current level
believ standard care pnh continu switch soliri ultomiri
next year reduc portion patient incomplet respons owe pk
breakthrough substanti improv dose regimen patient
howev ultomiri unlik fulli address subject substanti extravascular
hemolysis-driven anemia also target shouldnt impact nich
opportun
think unlik use broadli front-lin therapi
soliris/ultomiri well-entrench within pnh commun inhibitor
extens safeti real-lif efficaci databas like keep drug go-to
choic physicians/pati also wonder dose conveni
suffici compel broader use administ via sc infus time per week vs
ultomiri administ via iv alexion sc formul develop
may allow weekli less frequent administr could potenti come
market
term price believ price discount rel us soliris/ultomiri pnh
price could strategi facilit broader uptak howev unclear elast
market given question one consider compani balanc
differ price point differ condit explor price differenti across indic
challeng need optim price decis across portfolio
indic explor expect strategi data-driven becom clearer data
addit studi emerg
estim initi address popul rang pnh
patient expect could captur long-term sale given investor
gener expect trial success believ bulk valu current
reflect stock assign valu program assum
probabl success
pnh revenu build
market entri us eu/row
price us net gross price roughli pariti ultomiri
mainten price model discount us price eu row
market share target address popul us impli
penetr patient treat complement inhibitor seven year
pnh summari us pnh revenue- total eu pnh revenue- total row pnh revenue- total revenue- pnh us patient treat complement target launchpeakyr share market patients- gross price net price us pnh revenu charl martineau pm univers toronto novemb
companynamemoleculetargetrout adm dosingstatusachillion moleculefactor mg tid mg bidongo phase mono tx treatment nave add eculizumab data report monotherapi pt transit phase begin trial plan initi therapeuticscoversintick-deriv mg qdcomplet phase pt treatment nave met primari endpoint phase add-on trial capston intiati eu phase asset trial current recruit alnylam pharmaceuticalscemdisiran mg qwdiscontinuedapelli twice weekli subcutan infus mg on-going initiati june vs soliri phase pegasu trial enrol complet top-lin data due decemb ra mg/kg qd suggest pivot doseph extens on-going develop postpon roche/chugai nave explor load dose mg iv follow mg sc weeklyphas trial mg complet phase current moleculefactor boralopen label phase estimate enrol separ phase estimate enrol administr addit pozelimab monoclon volunt receiv iv load dose plu multipl weekli sc dose levelsphas on-going estimate week complement inhibitor treatment-nav patientsamynda complet phase plannedbiocryst moleculefactor doralphas proof concept treatment nave refractori pnh patient plan biosimilar monoclon dose mg qw first week mg week thereafterphas estimate current charl martineau pm univers toronto novemb
aiha offer addit sourc valu
creation hematolog
see potenti cad consid diseas patholog de-risk
competitor complement inhibitor believ cad could peak revenu
opportun
complement inhibit well-establish waiha believ develop
indic like target subset patient
autoimmun hemolyt anemia aiha group rare autoimmun condit driven
autoantibody-initi destruct red blood cell apelli studi two subtyp
aiha cold agglutinin diseas cad warm antibodi aiha waiha
approxim patient autoimmun hemolyt anemia peopl
us waiha individu us cad
compani on-going phase trial studi origin plan enrol patient
waiha patient cad earli result encourag particularli cad
discuss follow section compani plan commenc cad trial
earli compani indic juli continu evalu
patient waiha
figur initi studi aiha
believ develop cad higher likelihood success
mechanist complement play major role promot destruct rbc
initi data compet program valid approach indic
destruct waiha may also result igg-bound cell phagocyt spleen
macrophag antibody-depend cell-medi cytotox therefor complement
inhibit may fulli efficaci patient
introduct agglutinin diseas
primari cold agglutinin diseas cad condit affect patient us cad
rare autoimmun hemolyt anemia commonli found elderli symptom includ
anemia acrocyanosi bluish purpl color hand feet fatigu
underli caus cold agglutinin diseas vari diseas may idiopath primari
cad may caus certain bacteri infect lymphoid malign secondari
cad gener resolv follow treatment underli disord regardless
caus pathogenesi similar cold temperatur though patient may experi
symptom regardless ambient temperatur immunoglobulin usual igm bind red blood
cell form agglutin activ complement cascad ensu bind
surfac red blood cell blood move back bodi core warm
igm dissoci red blood cell howev remain attach red
blood cell trigger extravascular sometim intravascular hemolysi via macrophag
approv therapi primari cad approxim patient
classifi moder sever cad requir therapeut intervent initi patient
often prescrib off-label rituximab moder effect though durabl
may limit uncontrol studi discuss kol suggest
respons rate follow standard cours treatment iv weekli
week patient dont respond rituximab alon may receiv rituximab plu fludarabin
may effect case though toxic concern berentsen
improv rituximab therapi instantan may take month
signific symptomat effect note rituxan therapi typic effect month
averag retreat possibl though respons gener thought diminish
time
rituximab rel long time effect question long-term durabl result larg
number patient ultim requir transfus benefit transfus short-liv
perform chronic lead iron toxic along consider declin qualiti
encourag data de-risk futur develop cad
open-label trial enrol cad patient dose qd
dose qd mean age patient women
apelli releas suggest interim data european hematolog associ eha
congress june encourag improv seen across number endpoint
hemoglobin rose baselin g/dl g/dl day result sustain
day ldh level normal absolut reticulocyt count drop normal
rang figur figur detail
transfusion-depend patient respond left studi day
respect remain transfusion-depend patient requir
transfus mainten treatment one week start
figur hemoglobin level approach lower end
compani data data eha june
figur absolut reticulocyt count drop
compani data data eha june
figur cad consist sustain improv across
compani data credit suiss estim data eha june
gener well-toler grade treatment-rel
competitor sanofi valid complement reason target
treatment cad may cap market opportun
sanofi sutimlimab monoclon antibodi target classic complement
pathway develop cad asset origin develop north
therapeut acquir bioverativ up-front payment
develop regulatori sale mileston base result
hand patient bioverativ subsequ bought sanofi januari
administ symptomat cold agglutinin patient dose mg/kg
iv weekli week patient one-month washout period iv dose
resum everi week long-term extens
result trial compel efficaci respons rapid sustain
repeat primari cad patient saw hemoglobin level increas within day
commenc therapi averag increas one month primari cad patient
follow treatment one patient six normal hemoglobin level
three patient hemoglobin level figur
detail addit bilirubin level drop significantli evidenc therapi
physician spoken found result highli encourag believ rapid
onset action robust hemoglobin increas would significantli improv patient qualiti
washout period hemoglobin level drop bilirubin increas consist
resumpt diseas activ upon resumpt therapi revis dose
everi two week trend revers efficaci restor highlight
potenti benefit patient chronic dose solidifi iv dose regimen
number patient secondari mg/kg weeklymethod administrationivdur weekli dose follow mo washoutkey endpointshemoglobin levelsbilirubin red blood cell transfusionsphas studi charl martineau pm univers toronto novemb
figur phase chang
bioverativ disclos therapi demonstr persist efficaci without
relat advers event develop clinic relev neutral antibodi ole
month observ
two trial result expect cardin trial
open-label studi primari cad patient sever patient popul defin
recent occurr transfus cadenza trial random double-blind
placebo-control random trial primari cad patient rel less sever
patient popul patient studi dose iv everi two week
week consider rel program design
co-primari endpoint increas hemoglobin level g/dl g/dl
clinic meaning appear highli achiev base result phase
co-primari endpoint absenc transfus appear reason base phase
result easi measur
believ commerci launch sutimlimab possibl roughli
year ahead
cad market dynam revenu build
see credibl threat like limit market opportun
cad data date appear least compar lead
market addit sanofi advantag firmli entrench market via
sale hemophilia product doctor spoken treat
hemophilia cad
potenti offset threat subcutan infus like prefer
iv infus sanofi/bioverativ spoken past develop subcutan
formul although statu program quickli move
clinic unclear
assign po program base strong data posit
read-through sanofi also act complement pathway
current model peak opportun indic reflect
cardin phase phase single-armrandom double-blind placebo-controlledtarget wk screening/ week wk screen wk treatmentenrol criteriahbg g/dlhbg g/dlsymptomat primari cagdsymptomat primari cagd transfus past transfus past monthsprimari endpointsincreas hb g/dl normalizationincreas hb g/dl normalizationabs transfus wk transfus wk trial exclud patient rituxin monotherapi within month rituxin combin therapi within month prior annual revenue- ex-u annual revenue- total revenu cad moder sever launchpeakyr share market patients- gross price price annual net sale charl martineau pm univers toronto novemb
system nephropathi
addit option
apelli run basket trial sever differ type nephropathi diseas
kidney caus damag small blood vessel unit kidney
clean blood includ iga nephropathi membran nephropathi lupu nephriti
glomerulopathi figur detail indic
given compani report octob plan advanc clinic develop
lupu nephriti membran nephropathi still evalu pursu
addit studi subgroup patient iga nephropathi focu follow
discuss
figur nephropathi explor
overview
term adopt new classif system base
histopatholog kidney biopsi data defin group rare kidney diseas driven
dysregul complement cascad diseas result overact
altern complement pathway accumul kidney lead inflamm
patient typic present proteinuria protein urin hematuria blood urin
may also high blood pressur edema fluid retent fatigu time
patient may suffer sever irrevers kidney damag approxim children
adult develop end-stag renal diseas within year diagnosi requir
dialysi kidney transplant stay aliv approv treatment kidney
transplant provid temporari relief diseas recurr document almost
immedi kidney transplant result failur transplant patient
within year us diseas incid patient per year preval
patient smith et al
diagnosi diseas base kidney biopsi particular focu level
complement protein membran attack complex patient typic
low level plasma high level downstream complement
protein kidney evalu via immunofluoresc
natur history/th expect cours diseas may influenc underli caus
diseas instanc diseas may caus gain function mutat
upregul complement pathway loss function mutat downregul inhibitori
factor complement cascad autoantibodi variou activ regulatori
complement protein one studi found absenc mutat identifi
autoantibodi associ higher risk end stage renal diseas find
reconfirm studi iatropoulo et al prognost factor includ
estim glomerular filtrat rate egfr diagnosi lower wors percent tubular
atrophi higher wors percent cortic area interstiti fibrosi higher wors
smith et al detail
patient normal renal function proteinuria receiv support care
sever kidney inflamm high proteinuria requir aggress manag
approv treatment sever manag option vari
degre success
ace inhibitor angiotensin receptor blocker use address
high blood pressur proteinuria retrospect studi found agent
plasma exchang limit data approach mix result one
girl saw benefit plasma exchang success
remov nephrit factor remov protein prolong half-lif
howev work case
immunosuppres potenti decreas autoantibodi product
result mix one studi patient one subtyp
patient anoth subtyp patient icgn
found immunosuppress alter renal surviv servai et al
howev immunosuppress help differ studi patient
divid group mycophenol mofetil corticosteroid
immunosuppress treatment control patient remiss rate
significantli higher mycophenol mofetil arm patient vs
immunotherapi arm likewis patient mycophenol mofetil arm
patient immunotherapi arm progress end-stag renal diseas
compar patient control interestingli appear patient posit
nephrit factor may respond better treatment rabasco et al
eculizumab eculizumab brand name soliri inhibitor therebi act
downstream sever case report support use drug subset
patient nester et al addit open-label trial patient
show sign benefit month
eculizumab treatment patient reduc serum creatinin level one patient
mark reduct proteinuria one patient sign histolog improv
kidney transplant respons tend temporari one studi
patient receiv kidney transplant diseas recurr observ
patient usual within year transplant recurr confirm
median time graft failur month small number appear
women like recur lower baselin level associ
higher risk recurr recal level normal deplet patient
use kidney zand et al detail
apelli announc eight patient enrol open-label
glomerulopathi studi patient studi receiv via daili subcutan infus
primari endpoint studi chang proteinuria week
abstract inhibit underli diseas process
complement hyperact improv proteinuria provid addit detail trial design
earli result data eight subject present nov asn kidney week
studi enrol subject primari proteinuria mg protein/mg creatinin
egfr administ daili subcutan infus
potenti transit mg twice-weekli earli week three
subject one non-compli data includ abstract
two result show encourag trend
figur reduc proteinuria subject
believ valu assign indic could limit near-term base lack
substanti preced help frame efficaci pivot trial design fact
larger studi indic primari endpoint histolog index
potenti stricter endpoint limit still
complement inhibitor develop indic ahead ach-
factor achillion/alexion avacopan
factor novarti limit public data avail anecdot
compani seem de-emphasize develop indic
address popul patient us patient estim
affect think indic may support revenu opportun
rang though price complement inhibitor approv like
cap substanti upsid rang base dose regimen explor far pnh-like
price like
geograph atrophi could drive upsid
geograph atrophi ga area high unmet need fda-approv
therapi treat estim patient us
demonstr promis efficaci profil one largest phase
studi indic though question product profil remain
address phase program
see ga potenti high-valu option stock success
studi without major safeti concern could see sale approach even
modest assumpt though lower convict around probabl
success program
age-rel macular degener lead caus vision loss us
advanc treat neovascular wet signific patient
gener good long-term prospect patient account
remain signific unmet need treatment geograph atrophi ga
advanc form dri apelli estim affect roughli peopl us ga
character progress vision loss sever year owe retin cell death
eventu impair central vision diminish qualiti life fda-approv
treatment indic
figur age-rel macular degener advanc form
establish promis phase profil geograph atrophi filli
monthli inject led clinic meaning statist signific
reduct lesion size growth versu sham group
post-hoc analysi demonstr accentu treatment effect month
suggest greater efficaci longer dose period
off-treat period month show lesion start grow
faster pace reinforc efficaci signal seen first month like relat
drug
apelli conduct filli trial phase studi ga primari efficaci endpoint
chang squar root geograph atrophi lesion size baselin month measur
fundu autofluoresc imag
demonstr promis efficaci
ga uncertainti around product
profil remain expect program
address question
subject random receiv mg inject intravitr cc
volum monthli every-other-month sham inject monthly/every-other-month
respect treatment period last month imag measur ga lesion size
baselin month subject follow addit month without
treatment final lesion size growth month studi enrol total subject
one largest phase trial indic
figur filli phase studi ga timelin
geograph atrophyneovascular wet generalcharacteristicscharacter area degener retin pigment epithelium rpe cell photoreceptor visual impair irreversiblegrowth abnorm blood vessel retina may leak fluid caus vision loss potenti revers eventu form scar tissu lead perman central vision lossprogressionslowacutestandard careno fda-approv drug evid support benefit vitamins/supplementsanti-vegf avastin eyelea lucenti macugen late-stag age-rel macular charl martineau pm univers toronto novemb
baselin characterist gener balanc among studi arm
figur filli phase studi ga baselin characterist
month everi month cohort achiev reduct squar root lesion
growth versu sham group
result even compel present absolut lesion size growth
lesion size growth reduct versu sham group endpoint util roch
lampalizumab studi phase primari endpoint align fda
efficaci seem pick time accentu treatment effect month
suggest longer dose period could potenti lead greater clinic benefit
figur phase growth reduct accentu month
studi also enrol patient bilater diseas creat intrapati control phase
data demonstr strong trend lesion growth trajectori versu untreat fellow eye
drug discontinu month led lesion growth close normal pace
reinforc efficaci signal seen patient on-treat portion studi
figur phase ga worsen group treatment
doctor spoken indic result potenti clinic meaning
even growth differ absolut lesion size would meaning expert
opinion though somewhat patient depend also highlight sever efficaci
marker point right direct unlik previou studi complement inhibitor
indic potenti reinforc efficaci signal seen phase
physician spoken believ efficaci promis though
question overal profil remain
demonstr remark efficaci phase filli studi sever factor
indic drug activ agent ga notabl
respons correspond dose frequenc
stat-sig reduct lesion growth versu sham sham perform in-lin
studi
treatment discontinu month led lesion grow higher
pace similar sham
encourag efficaci profil consult mention central debat
safeti profil ga especi new onset exud seen studi
patient dri may spontan develop/convert wet time wet
dri convers also possibl data point suggest level
interconnect two manifest advanc macular degener
wet patient develop ga follow year seven-up
signific portion patient may geograph atrophi lesion one eye
choroid neovascular cnv fellow eye
retrospect uk ga studi subject ga eye develop cnv
new onset exud rate subject monthli studi arm compar
everi month sham group filli patient
new onset cnv discontinu treat anti-vegf therapi
visual acuiti preserv patient develop wet non-treat
period fellow eye wet baselin
observ studi report rate cnv onset year year
patient bilater ga baselin cnv rate consist onset
cnv seen two phase studi lampalizumab patient cnv one eye ga
document much higher rate convers year
year eye ga
final compani indic minor subject report new
onset exud confirmatori diagnosi fluorescein angiographi
confirm present minim diseas compar classic present wet
overal expert believ may provid clinic meaning benefit patient
wet well-character current anti-vegf therapi efficaci control
diseas high success net benefit patient develop cnv
treat also signific decreas ga lesion growth seem posit
expert other skeptic would like see addit data matter
phase program includ two trial derbi oak enrol subject
random monthly/everi month respect sham control arm
chang inclusion/exclus criteria filli phase
primari endpoint chang baselin month total area ga lesion
studi eye base fundu autofluoresc compar squar root
chang examin phase
chang phase phase
phase studi doubl mask frequent imag time point
studi also includ two vision function assess read speed microperimetri apelli
also includ two patient-report outcom endpoint nation institut visual
function questionnair nei function read independ fri
doctor consult believ key secondari endpoint may
help drive commerci adopt increas patient intent seek treatment offset
drawback potenti frequent dose regimen
crucial chang help elucid unlik phase subject
develop exud phase studi continu receiv
combin anti-vegf believ import chang program
protocol remain biggest overhang program
expect phase studi
valid efficaci signal seen phase
determin every-other-month dose profil compar monthli
clarifi frequenc sever new onset exud patient
compar sham evolv time
determin safeti efficaci complianc subject requir combo
anti-vegf well frequenc length anti-vegf therapi
derbi oak studi expect initi base lampalizumab
experi believ apelli may take two year patient enrol potenti
commerci launch
point refer roch two phase pivot trial lampalizumab enrol
patient primari endpoint chang baselin ga area assess fundu
autofluoresc week first patient studi enrol
compani announc spectri meet primari endpoint sep
figur lampalizumab phase trial
final studi two case confirm endophthalm addit one
case presum endophthalm cultur test neg bacteri growth
incid rate endophthalm per inject compani believ rate
like relat use freeze-dri materi requir reconstitut prior inject
carri risk contamin util liquid formul instead
expect reduc risk
octob apelli disclos case non-infecti inflamm patient dose
on-going program implement voluntari paus dose run non-human
studi review manufactur process compani believ inflamm may
caus impur api introduc scale apelli modifi
manufactur process enough suppli conduct entir phase
program enrol two phase ga trial derbi oak resum apelli
continu expect trial fulli enrol end first quarter
delay origin timelin
might trick complement role ga
geograph atrophi multi-factori diseas mechan complement-medi
damag retina fulli character howev gener accept
complement may play role dri owe cell damag caus inflamm
trialphas chroma phase spectriphas derbyphas criteria arm lampalizumab lampalizumab placeboprimari chang baselin ga area assess fundu autofluoresc week time frame baselin week secondari chang bcva addit measur visual functionno evid prior activ choroid neovascular cnv eyesarm placeboprimari chang baselin month total area ga lesion studi eye base fundu autoflouresc secondari chang bcva addit measur visual functionneovascular fellow eye charl martineau pm univers toronto
trigger increas level activ macrophag
microglia may attack retin cell deposit surfac
complement inhibitor studi indic previous abl
demonstr compel result clear sign competit efficaci
alexion soliri complet phase studi investigator-sponsor trial
enrol subject evalu soliriss eculizumab safeti efficaci
treatment ga soliri decreas growth rate ga significantli versu
placebo week author paper specul intravitr dose
could led differ result inhibit might enough
reduc lesion growth sinc damag could continu caus
roch lampalizumab lampalizumab complement factor inhibitor phase
result mahalo studi demonstr reduct rate area
ga month monthli intravitr inject cohort
treatment effect evid every-other-month dose cohort post-hoc
analysi identifi sub-popul enrol subject specif allel
complement factor treatment benefit reduct base
result roch took candid phase howev lampalizumab
demonstr reduct mean chang ga lesion area compar sham
treatment one year week two phase trial ga genet
biomark subgroup signific effect consist phase
iver bio zimura recent iver disclos top-line data studi zimura
complement inhibitor ga posit result though question remain
studi show reduct mean rate ga growth month
mg arm compar placebo stat-sig though dont think
clear sign dose respons trial also enrol subject
extrafov lesion make comparison studi difficult compani
also report incid choroid neovascular cnv untreat fellow
eye patient studi eye patient sham
control group patient zimura mg group patient
zimura mg group
mechanist soliri inhibitor would impact damag
retin cell lampalizumab factor inhibitor target altern pathway
perhap obtain level inhibit necessari avoid deposit cell apl-
inhibit differenti target may substanti advantag previou
complement inhibitor studi ga support phase data addit sever
polymorph gene report strong associ
corrobor mechanist approach explor apelli ga
commerci adopt highli depend final product profil
one key debat stock signific push/pul bull bear
commerci adopt ga
bear highlight slow progress diseas notic improvement/revers
therapi treatment burden monthli inject wamd convers higher
rate inflamm advanc age patient popul potenti reason
commerci failur wamd patient gener suffer acut vision loss
notic improv anti-vegf therapi drive overal complianc even still
patient receiv roughli seven inject per year treatment burden ga patient
monthli inject notic improv therapi slow progress
pose key challeng adopt
bull highlight high unmet need treatment option indic clear
efficaci signal phase largest sampl size stat-sig without need post-hoc
analys amen safeti profil drug consult emphas
patient eager treatment option even slow diseas progress
overal believ drug moder adopt across board high adopt
patient advanc diseas fellow-ey vision impair lesion close fovea
howev acknowledg complianc could potenti subpar
geograph atrophi revenu build
price us gross price per eye gross-to-net rebat
complianc rate consid monthli inject regimen high
treatment burden associ slow progress diseas
market share us eu translat treat
patient peak us
geograph annual eu annual revenue- total revenu geograph atrophi diagnos target launchpeakyr share market number treat gross price per price per annual net sale phase trial on-going expect complet enrol month treatment window johnson complet statu unknown iver biozimuraoth nucleic phase top-line readout oct futur trial yet announc stealth/alexionelamipretidepeptidemitochondrialphas studi initi expect complet enrol earli week treatment period ionis/rocheionis-fb-lrxantisensefactor bphase dose-rang studi on-going initi estimate week treatment period allerganbrimonidin ddssmall moleculealpha adrenerg receptorphas studi suspend late statu futur trial gallego trial initi week treatment period astella proof concept estimate charl martineau pm univers toronto novemb
valuat risk
arriv target price use blend valuat approach includ
product-bas dcf estim premium
dcf model assum discount rate owe apelli statu late clinical-stag
biopharmaceut compani assign per share pipelin valu larg reflect
opportun expans nephropathi waiha potenti
complement-medi diseas equat revenu perpetu start
year
detail dcf compon includ follow
second valuat scenario support target reflect dcf
analysi assum potenti synergi potenti acquisit reduct
 expens increas revenu
weight scenario target price owe unencumb
statu late-stag clinic trial pnh ga
probabl success
standard probabl success forecast phase asset phase
asset phase asset asset nda/bla stage slight
adjust base histor probabl success specif diseas categori
standard mind assign follow probabl success estim aplss pipelin
ga lower typic phase standard reflect current
paus dose subject program balanc unknown rel
new onset exud overal safety/dos regimen well commerci
pnh higher typic phase standard consid
compel efficaci establish date
cad in-lin standard consid blend
expect commenc
apelli net cash project cash use oper
price posga revenu charl martineau pm univers toronto
blue sky valuat reflect probabl success po pnh
po geograph atrophi po
cold agglutinin diseas dcf weight lower
discount rate grey sky reflect failur pnh studi
lead elimin pnh/cad program valuat concern
program weight
regulatory/clin risk includ limit trial enrol delay poorli design
studi inadequ endpoint power neg safety/efficaci signal neg
delay difficulti recruit patient clinic trial
failur demonstr adequ efficaci registr trial pnh ga
safeti signal higher rate new onset exud high rate infect
failur establish efficaci cad
manufacturing/suppli risk includ limit suppli disrupt product batch
adher qualiti standard manufactur shutdown due contamin technic
difficulti produc function complex molecul delay construction/certif
lack materi compar among
inadequ
suppli interrupt multipl global clinic trial conduct
issu roll commerci on-bodi patch pump system deliveri
commerci risk includ limit lower-than-expect adopt drug
target popul competit clinical/exist agent payor-impos access restrict
price reform and/or restrict and/or control specif
competit agent across multipl indic explor
addit risk includ financ compani need rais addit capit
subject market conditions/uncertainti complet transact
apelli inc stmt million except share ga- pnh- cad- other- total revenue- cogs- gross profit- other- oper invest interest expense- incom loss incom incom tax expens benefit net incom dilut net loss/shar apelli balanc sheetal cash expens total current asset total portion lt current total current lt total total sharehold liabil sharehold charl martineau pm univers toronto novemb
apelli flowal incom depreci amortization- stock base comp chang deriv liability- chang oper assets/li ar- inventory- prepaid accru exp net cash use oper purchas fix assets- sale fix assets- purchase/sal investments- invest activity- net cash use invest activities- proce issuanc debt- repay debt- proce issuanc repurchas stock- proce issuanc stock financ net cash provid financ effect exchang net increas decreas begin end charl martineau pm univers toronto novemb
compani mention price
